CB OG

@Veganhippo21 @DeepValueBagger ….and there is *a lot* of crappy dubstep out there….

@CharlesStonkson @DeepValueBagger Yeah that’s true Many many are just meh Got to explore here now

Went to gym, worked with some HS guys on some basketball moves….good day. And I realized I fucking hate dubstep!!!! Hate that shit!!! Gimme Edm real techno trance and leave that shit dubstep out pls Ahhhhh Who listens to this shit

@Veganhippo21 @DeepValueBagger Yea I dk…I always thought it sucked when I was first getting into edm until seeing a few good live shows. The difference between crappy trance etc and crappy dubstep is crappy trance doesn’t physically hurt to listen to. I only really like the top 1-2% of any genre

@CharlesStonkson @DeepValueBagger lol I maybe have to check it out Last time my ears got raped bad

@Veganhippo21 @DeepValueBagger Booo….dubstep is one of the few types of music in the past two decades that has actually introduced new types of sounds and concepts, not just copying others. Go to EDC before you hate

@DeepValueBagger lol…yeah my friend that’s musician claims this is not music (he is piano guitar guy). I shall see what to do now

@Veganhippo21 Beautiful, sunny and mid60s today….no blizzard, no fire storm…..

Even he can’t resist golden gates! City by the bay! Lol 😂

Reflecting on the $SAVA Journey: Lessons Learned from a Phase 3 Failure I’ve had some time to reflect on the current state of $SAVA following the disappointing results of the Phase 3 trial. The trial failed to achieve any significant improvement over placebo on primary or secondary endpoints, including biomarkers. This is a significant setback for the program. Rick's transparency was evident in the timing and nature of the announcement. The company could have spent more time analyzing subgroups to find a silver lining, but instead, they chose to announce the results without attempting to spin the outcome. This honesty speaks volumes—they clearly didn’t see a path to a commercial success in the initial data. I still hope the detailed data will reveal something of value. Based on what we heard from patients, clinics, $SAVA, and the earlier data, I was confident that simufilam was a clear winner. However, the trial results strongly suggest that the drug does not have a meaningful effect on patients. Failing every endpoint is a sobering outcome. The detractors were right about the lack of a placebo-controlled Phase 2 trial. Despite having access to extensive Alzheimer's placebo data, none of it matched the specifics of simufilam’s trials. The placebo performance in Phase 3 fell far below expectations, likely due to the way screening was executed. This wasn’t a matter of chance. A blinded placebo trial in Phase 2 could have flagged this issue earlier. The biomarker data is another major disappointment. It appears to show no signal of efficacy. I wonder whether there was an initial response that diminished over time or simply no movement at all. It’s possible certain subgroups or cohorts could reveal something meaningful, but we won’t know until the data is sliced and analyzed further. Looking at the data through the lens of tau levels, as donanemab did, might provide insights. However, fully closing out the REFOCUS study and analyzing the data will take months. I am eager to see the detailed results to better understand what happened. In reviewing the data, the Cassava team will certainly see evidence of sabotage if it exists. This is very very unlikely in my opinion because of the rigorous controls, many backups of data, masked data availability, and etc. I see little point in belaboring thoughts the outcome was caused by hacking or manipulation. On a personal note, I want to address my holdings in $SAVA. I have fallen below the 5% reporting threshold due to a transfer into my irrevocable trust. Please don’t make any assumptions about my holdings when deciding whether to buy, hold, or sell. Do your own investment research and continue to make your decisions. While I will continue to follow the story and communicate with the team, my personal optimism for simufilam’s commercial potential is now below 5%. Cassava Sciences has been a profound learning experience for me. I still believe the company faced immense and unfair challenges, particularly from short sellers and the media who made this journey more difficult than it needed to be. I do believe many of the individuals that participated in this attack are evil people. I plan to step back from leading CureGuardian.org, though I will continue to support its mission with funding and guidance as I transition leadership to others. Cure Guardian will remain and flourish as to fight for those that want to help the world cure disease against the evil we have exposed that want to stop or hinder efforts to cure disease or slow research. I am deeply saddened for the patients on simufilam, many of whom are convinced the drug was helping them. Their experiences remain an important piece of this puzzle and it really could be helping them. I will work with the $SAVA team to explore paths for continued access to the drug, though I honestly don’t know what those steps might look like at this point. Programs exist at the FDA (compassionate use and right to try ) and drugs and supplements at stores now. This failure is a personal blow, and I need time to focus on my family and myself as I process this setback. I remain committed to helping find a cure for Alzheimer’s disease and supporting those affected, including myself, given my own high risk for developing AD. To the $SAVA team and the incredible community I’ve met along this journey: thank you. I value the connections we’ve built and will continue to maintain them. This is not the end of my efforts, but it is a moment of recalibration.

@arkabagchi24 lol if you want, but don’t be a douche. There have been literally dozens of ppl joining to gloat, call us idiots etc. and yea, we know already lol.

@CharlesStonkson All good man - turns out counting red flags is a lot like counting drinks... stopping at 3-4 usually works out better than going for a dozen. & much like a rough hangover the best cure for $SAVA trauma is group therapy. Any chance you could lift my $SAVA discord ban & invite me?

@arkabagchi24 GG - you guys were right. Can’t say I didn’t see all the red flags, just figured ~3-4 is the sweet spot. Didn’t realize the dozen or so painfully obvious ones were all 100% legit until too late. Apologies for being such a douche to you, hope you’ve been doing well

@Veganhippo21 @netcapgirl lol this tweet goes hard

@netcapgirl No-body wanna be burry bro (he blocked me). We are all about Patrick B Check it out

many such cases

@Veganhippo21 Nice…I’m hoping IKT drops results early next week I can add another 2k-ish

Added 5,000 shares of $sava at 27.33

@Veganhippo21 lol classic

My daughter and I got matching shirts From what movie? 🎥 Tell me

@MartinShkreli This is also an incredibly stupid post that shows you don’t have a scientific education of any kind and completely lack a fundamental understanding of structural biology / related fields

re filamin A and $SAVA fraud: filamin is a very large protein and molecular dynamics (AMBER, GROMACS, etc.) will reveal the intrinsic molecular motions. "altered" is a strange word a structural biologist would never use. altered could mean post-translational modifications, which doesn't seem to be what they're implying. it could mean mutation, which would be rather easy to test, so it can't be that. the idea that they can't specify it should worry you. they probably mean 'misfolded'. all that they mention is isoelectric point. pI is useless for very large proteins like filamin a. there are far better assays for determining this. they didn't do them. finally, if you look at the region it is purported to bind, it's solvent facing and unlikely to meaningfully change in an 'altered' state. even if 'altered', you cannot contrive a conformation that gives strong binding.

@MartinShkreli Yea…exactly lol

@CharlesStonkson ????

The $SAVA patent US9340558 is the first disclosure of simufilam, a purported picomolar binder of filamin A. Unfortunately, the patent discloses micromolar binding affinity. See compound C0104M.

@Veganhippo21 @davegirouard @Upstart You slip some toad venom in the coffee over there or something??📈

$upst I am clocking in in a minute guys! See you soon @davegirouard If not us who??

@Veganhippo21 Nice, love that spot

When $upst hits 52 week high but you chill about it in the clouds ☁️ Bro 😎

@Veganhippo21 Had some Oct18 $30s I offloaded for a nice profit this AM 👍

OUCH 4x on $sava calls

@Veganhippo21 Honestly I’m thinking tsla puts….

Let’s call this exit liquidity lol 😂 $TSLA - GOLDMAN RECOMMENDS BUYING TESLA CALL OPTIONS BEFORE TWO BIG CATALYSTS IN OCTOBER Imagine giving advice to retail on CALL buying lol 😂 dude !!!!

@BiotechElmo Change is the only thing constant in life

@Veganhippo21 Historically rate cuts have always have led to short term pull back from what I’ve seen

25pts incoming and a flush. I am so curious how this pump to 50pts will play out. No person knows

@MrZackMorris ☠️

@MrZackMorris Bro it’s dead dead

$TCDA Letting it do its thing and then adding more. I love dead cat bounces